Skip to content

US · QTTB · BIOTECHNOLOGY

Q32 Bio Inc. (QTTB) intrinsic value and stock valuation

$8.34as of 2026-11-21 · Mkt cap 199.31M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Q32 Bio Inc. DCF and intrinsic value

InvestorsCraft values QTTB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from QTTB’s statements →

Q32 Bio Inc. Graham Number

Graham Number: $13.65d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Waltham, MA 02451 q32bio.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$53.7M+81.9% 5y CAGRd
20162025
Net income
$29.8M
20162025
Free cash flow
-$-33.54M
20162025
Total equity
$42M-26.5% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$53.7M$0.00-$-6.65M$3.21M$34M
Operating income$16.9M-$-66.1M-$-48.26M-$-39.23M-$-95.95M
Net income$29.8M-$-47.73M-$-53.74M-$-42.81M-$-95.76M
EPSd$2.42M-$-3.91M-$-16.69M-$-13.42M-$-31.19M
Operating cash flow-$-33.54M-$-67.72M-$-18.68M-$-10.96M-$-109.75M
Capital expenditure$0.00-$-70K-$-10K-$-2.48M-$-2.4M
Free cash flow-$-33.54M-$-67.79M-$-18.68M-$-13.44M-$-112.15M
Total assets$61.8M$92.3M$47.1M$61.8M$211.7M
Total debt$15.3M$18.9M$50.8M$44.7M$23.9M
Net debt-$-32.95M-$-59.06M$25.2M$840K-$-84.45M
Total equity$42M$5.67M-$-182.92M-$-130.71M$169.7M
Cash and short-term investments$48.3M$78M$25.6M$43.9M$155.9M
Income statement
20252024202320222021
Revenue$53.7M$0.00-$-6.65M$3.21M$34M
Cost of revenue$390K$490K$500K$2.6M$9.54M
Gross profit$53.4M-$-490K-$-7.15M$610K$24.4M
Research and development expenses$19.2M$48.1M$31.7M$35.8M$93.1M
Selling, general and administrative expenses$17.7M$18M$9.88M$10.1M$6.76M
Other expenses-$-390K-$-490K-$-500K$0.00$20.5M
Operating expenses$36.4M$65.6M$41.1M$45.9M$120.4M
Cost and expenses$36.8M$66.1M$41.6M$45.9M$129.9M
Interest income$2.2M$3.9M$0.00$3.23M$180K
Interest expense$1.1M$300K$1.5M$0.00$0.00
Depreciation and amortization$390K$490K$500K$370K$9.54M
Ebitda$31.3M-$-45.3M-$-47.76M-$-38.85M-$-86.22M
Operating income$16.9M-$-66.1M-$-48.26M-$-39.23M-$-95.95M
Total other income/expenses, net$12.9M$18.4M-$-5.17M-$-3.52M$180K
Income before tax$29.8M-$-47.71M-$-53.42M-$-42.75M-$-95.76M
Income tax expense$0.00$20K$320K$60K$0.00
Net income$29.8M-$-47.73M-$-53.74M-$-42.81M-$-95.76M
Weighted average shares outstanding$12.3M$12.2M$3.22M$3.19M$3.07M
Weighted average diluted shares outstanding$12.3M$12.2M$3.22M$3.19M$3.07M
Balance sheet
20252024202320222021
Cash and short-term investments$48.3M$78M$25.6M$43.9M$155.9M
Net receivables$0.00$560K$760K$1.06M$0.00
Inventory$0.00$0.00$0.00$1.75M$0.00
Total current assets$55.1M$81.9M$28.7M$46.9M$191.9M
Property, plant and equipment, net$6.08M$7.09M$8.08M$9.17M$17.9M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$650K$2.6M$5.65M$25.8M$1.95M
Total non-current assets$6.73M$10.5M$18.3M$14.9M$19.8M
Total assets$61.8M$92.3M$47.1M$61.8M$211.7M
Accounts payable$880K$2.99M$3.47M$1.44M$2.37M
Short-term debt$6.93M$3.71M$1.42M$32.9M$250K
Deferred revenue$0.00$0.00$0.00$14.5M$3.21M
Total current liabilities$11.4M$16.5M$14.1M$57.9M$17.2M
Long-term debt$8.42M$15.2M$49.4M$11.9M$23.7M
Deferred revenue, non-current$0.00$0.00$0.00$11.3M$1.16M
Total non-current liabilities$8.42M$70.2M$215.9M$134.6M$24.8M
Capital lease obligations$4.94M$6.25M$6.79M$7.26M$23.7M
Total liabilities$19.8M$86.7M$230M$192.5M$42.1M
Common stock$0.00$0.00$0.00$10K$10K
Retained earnings-$-204.99M-$-234.81M-$-187.08M-$-429.14M-$-424.13M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$-400K-$-10K
Total equity$42M$5.67M-$-182.92M-$-130.71M$169.7M
Total investments$650K$2.6M$5.65M$25.8M$49.4M
Total debt$15.3M$18.9M$50.8M$44.7M$23.9M
Net debt-$-32.95M-$-59.06M$25.2M$840K-$-84.45M
Cash flow statement
20252024202320222021
Net income$29.8M-$-47.73M-$-53.74M-$-42.81M-$-95.76M
Depreciation and amortization$390K$490K$500K$370K$9.54M
Stock-based compensation$5.25M$4.39M$1.43M$1.24M$0.00
Change in working capital-$-4.04M-$-9.64M$26.3M$26.9M-$-41.8M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-2.11M-$-1.04M$2.03M-$-1.24M-$-2.49M
Net cash provided by operating activities-$-33.54M-$-67.72M-$-18.68M-$-10.96M-$-109.75M
Investments in property, plant and equipment$0.00-$-70K-$-10K-$-2.48M-$-2.4M
Acquisitions, net$0.00$0.00$0.00$130M$0.00
Net cash used for investing activities$7M$19.9M-$-10K-$-2.47M-$-50.79M
Common stock issued$0.00$42M$110K$70K$52.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-3.12M$95.1M$410K$30.1M$52.2M
Net change in cash-$-29.67M$47.4M-$-8.37M$16.7M-$-109.05M
Cash at end of period$48.9M$78.6M$25.6M$49.5M$108.4M
Operating cash flow-$-33.54M-$-67.72M-$-18.68M-$-10.96M-$-109.75M
Capital expenditure$0.00-$-70K-$-10K-$-2.48M-$-2.4M
Free cash flow-$-33.54M-$-67.79M-$-18.68M-$-13.44M-$-112.15M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Q32 Bio Inc.

        Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.

        CEO
        Jodie Pope Morrison
        Employees
        22
        Beta
        -0.33

        Explore

        Frequently asked questions

        What is the intrinsic value of Q32 Bio Inc. (QTTB)?

        InvestorsCraft does not currently publish an intrinsic value for QTTB. How the IC value is calculated.

        Is QTTB undervalued?

        InvestorsCraft does not publish an undervaluation signal for QTTB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.